Our Focus
Our research efforts are focussed on:
(1) Elucidating the molecular and cellular mechanisms that control tumor cell behavior. We continue to uncover pivotal determinants by which the cytokine TGF-b switches non-invasive cancer cells into aggressive therapy-resistant cancer cells.
(2) Targeting tumor-promoting signaling pathways to develop more effective cancer therapies. For example, we are developing bifunctional antibodies to inhibit TGF-b-induced pro-tumorigenic responses in a cell type-specific manner. In addition, we are developing bifunctional small molecules that recruit cancer-inducing proteins to the proteasome for degradation.
(3) Investigating the role of tumor-derived extracellular vesicles (EVs) in inter-cellular communication and their use for early cancer detection and therapy response monitoring.We have been able to detect and isolate tumor-derived EVs using an agent that specifically binds an oncofetal-specific protein modification.
Two main questions that are being addressed:
(1) How can we selectively block TGF-β-induced tumor-promoting responses while preserving its essential role in maintaining tissue homeostasis
(2) Can tumor-derived EVs be used for early cancer detection and monitoring, and how do they promote cancer progression?
About Peter ten Dijke
Peter ten Dijke
My Research
Peter ten Dijke received his Ph.D. degree in 1991 from Wageningen University, The Netherlands based on his research on the identification of the third isoform of TGFβ performed at Oncogene Science, Inc., New York, USA. He did his postgraduate studies with Kohei Miyazono and Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR), Uppsala, Sweden. In 1994, he became group leader at LICR and moved in 1999 to the Netherlands Cancer Institute, Amsterdam, The Netherlands. In 2005, he became a professor of molecular cell biology at Leiden University Medical Center.
The overall aim of our work is to obtain a fundamental understanding on how cells communicate with each other, how this contributes to cancer progression when it goes awry ,and how we can manipulate it for therapeutic benefit. We use innovative integrated biological, genetic and chemical approaches to monitor and manipulate dynamic signal transduction processes. In particular, our research is focussed on elucidating the molecular mechanisms by which the multifunctional TGF-b family cytokines maintain tissue homeostasis and promote cancer progression.
Breakthrough discoveries were the identification and functional characterization of TGF-b family cell surface receptors and their downstream SMAD effector proteins. Moreover, we identified pivotal (druggable) regulators of TGF-b-induced epithelial of cancer cell plasticity and metastasis. Our research on how TGF-β controls tumor angiogenesis have led to new targeting agents that are being tested clinically. More recently, new insights were obtained into how ubiquitin modifications of TGF-β receptors and SMADs control their function and stability. The E3 ubiquitin ligases and deubiquitinating enzymes that were identified are novel targets for (immune) oncology drugs.
Awards
- 2025: Best Oral Presentation Award, Netherlands Society for Extracellular Vesicles (NLSEV) Annual Conference, awarded to Austin Enciso Martinez
- 2025: Prof. Dr. E. L. Noach Prize for Best Bachelor's Thesis, Leiden University, awarded to Van Anh Ho
- 2022: Marshall R. Urist Lecture Award
- 2021: Elected Member of Academia Europaea
- 2018: Elected Member of the Royal Netherlands Academy of Arts and Sciences (KNAW)
- 2016: Elected Member of the European Molecular Biology Organization (EMBO)
- 2015: Noreen Cunningham Lecture Award
- 2015: FEBS National Lecture Award
- 2015: Chang Jiang Scholar Award, Chinese Ministry of Education
- 2010: LUMC Education Prize for Best Frontiers in Science Course, Master's Programme in Biomedical Sciences
- 2006: NWO Vici Grant
- 2005: Honorary Doctor of Medicine, Uppsala University, Sweden
- 1998: Small Fernström Prize for Promising Scientists in Sweden
- 1992–1993: EMBO Long-Term Fellowship
Key Publications
- 2026 | Deciphering the regulatory landscape of enhancer RNAs in health and disease | Qian Wang et al. | Signal Transduction and Targeted Therapy | View publication
- 2025 | circTGFBR2(3-6) acts as an assembly platform for RNA-binding protein IGF2BP3 and TGFBR1 mRNA to enhance breast cancer cell plasticity | Qian Wang et al. | Cell Death & Differentiation | View publication
- 2025 | Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1-WAVE2 interaction | Matthias Müller et al. | Proceedings of the National Academy of Sciences | View publication
- 2025 | Extracellular Vesicles Secreted by Cancer-Associated Fibroblasts Drive Non-Invasive Cancer Cell Progression to Metastasis via TGF-β Signalling Hyperactivation | Adilson Fonseca Teixeira et al. | Journal of Extracellular Vesicles | View publication
- 2025 | Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity | Chuannan Fan et al. | Nature Communications | View publication
- 2025 | SMAD3 and p300 complex scaffolding by long non-coding RNA LIMD1-AS1 promotes TGF-β-induced breast cancer cell plasticity | Chuannan Fan et al. | Nucleic Acids Research | View publication
- 2025 | Surface-Associated Proteins on Extracellular Vesicles Remodel the Tumor Microenvironment by Potentiating TGF-β Signaling in a Contact-Dependent Manner | Chao Li et al. | Advanced Science | View publication
- 2025 | Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles | Agustin Enciso-Martinez et al. | Journal of Extracellular Vesicles | View publication
- 2025 | TGM6 is a helminth secretory product that mimics TGF-β binding to TGFBR2 to antagonize signaling in fibroblasts | Stephen E. White et al. | Nature Communications | View publication
- 2025 | The TGF-β mimic TGM4 achieves cell specificity through combinatorial surface co-receptor binding | Shashi P. Singh et al. | EMBO Reports | View publication
- 2023 | ST3GAL5-catalyzed gangliosides inhibit TGF-β-induced epithelial-mesenchymal transition via TβRI degradation | Jing Zhang et al. | The EMBO Journal | View publication
- 2022 | USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII | F. Xie et al. | The EMBO Journal | View publication
- 2020 | Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFβ-Induced breast cancer metastasis | S. Liu et al. | Clinical Cancer Research | View publication
- 2013 | TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis | L. Zhang et al. | Molecular Cell | View publication
- 1997 | Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling | A. Nakao et al. | Nature | View publication
Members
| Peter ten Dijke Group leader | Agustin Enciso Martinez PostDoc | Chao Li PhD student |
| Chuannan Fan PhD student | Weixin Liao Phd student | Dima Almandawi Technician |
| Emma Boerrigter PhD student | Gerardus van der Zon Technician | Jiying Zhang Phd student |
| Jun Yang Ong Postdoc | Kun Fan Phd student | Maarten van Dinther Technician |
| Marius Wits PostDoc | Midory Thorikay Analyst | Qian Wang Post Doc |
| Shaima Abdalla Phd student |